You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

Positive appraisal for Eisai’s Kisplyx in combination with MSD’s Keytruda

The therapy is as an option for untreated intermediate or poor-risk advanced renal cell carcinoma (RCC) in adults, in circumstances when nivolumab with ipilimumab would otherwise have been offered.